Avacta Group Plc’s (LON:AVCT) chief technology officer, Dr Matt Johnson, will present new data for the firm’s Affirmer range of research tools and diagnostics reagents at the Biomarkers and Precision Medicine Congress (BPMC) in San Diego on 12 October.
The biotech company said Johnson would present data showing how the Affimer technology can be used to simplify diagnostics and other immunoassays, as well as showing that immunoassays built using Affimers perform as well as, and better than, equivalent assays built using antibodies.
READ: Avacta rises as it secures licensing deal with New England Biolabs for Affimer technology
Avacta added that Johnson would also speak about a class of Affimers that captures antibodies but only when the antibodies are bound to their own targets, offering a route to improving an important type of diagnostic test to have a more specific and clearer result, the commercial potential of which was “significant”.
The BPMC gathers over 300 delegates from leading biotech companies, global pharma organisations and internationally renowned academic institutions to discuss key issues in biomarker research, companion diagnostics, personalised medicine and clinical biomarkers.